Santhera Finds ‘Elegant Solution’ For Its Finances With Catalyst DMD Drug Deal
US Rights To Vamorolone Licensed For $90m Upfront
The Swiss rare diseases firm Santhera has signed a licensing deal for its Duchenne muscular dystrophy drug vamorolone, which could be launched in both the US and the EU by the end of the year, paying off short-term debt and cleaning up the balance sheet.
